NCT07211815Not yet recruiting
Dosimetric Differences and Clinical Significance Analysis Between Body Gamma Knife and VMAT Radiotherapy for Primary Liver Cance
Source: ClinicalTrials.gov · Last updated 8 Oct 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
To fill in the "Brief Summary" field, you need to provide clear, easy-to-understand information about the study for patients, families, and healthcare providers. Here's a suggested summary: This study compares the dosimetric features and clinical effects of body gamma knife and VMAT radiotherapy for locally advanced primary liver cancer. We retrospectively analyze 20 patients from Chifeng Tumor Hospital who cannot or refuse surgery. For each patient, we will develop both body gamma knife and VMAT radiotherapy plans. Then, we'll compare the dose distribution in the tumor target (including conformity index and homogeneity index) and the radiation exposure to organs at risk (such as the spinal cord, stomach, and liver). The goal is to find out which radiotherapy approach is more beneficial, so patients, families, and healthcare teams can better understand how this research supports treatment decisions.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 30 (estimated)
- First submitted
- 22 Sept 2025
- Start date
- 1 Nov 2025
- Primary completion date
- 1 Jun 2027
- Lead sponsor
- Chifeng Tumor Hospital
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07211815
What you commit to
- Study type: Observational
- Planned participants: 30
- From 1 Nov 2025 to the primary completion date, 1 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Cerebrovascular accident within 6 months before enrollment.
Other illness
- History of portal hypertension, esophageal variceal bleeding, or related conditions.
- History of anti-RHCC treatment or spontaneous tumor rupture.
- Postoperative pathology indicates metastatic cancer or other primary cancers.
- Poorly controlled acute or active infection; severe mental illness.
- Pregnant or lactating women; presence of other serious underlying diseases.
Lab values
- Severe lung disease; serum creatinine \> 1.25×the upper normal limit.
Other
- Suspected systemic or local lymphadenopathy on imaging.
- Currently participating in other clinical trials; refusal to provide informed consent.
Who the study is looking for
- Aged 18-75 years.
- Clinically or pathologically confirmed primary liver cancer; unsuitable for or - refusing surgery, with single tumor diameter ≤5 cm and ≤5 nodules.
- ECOG PS score 0-1.
- Liver function: Child-Pugh grade A or B.
- Prothrombin time (PT) \< 4 seconds above the normal control range.
- No hepatic encephalopathy or moderate to large ascites.
- Renal and cardiopulmonary function basically normal.
- Gastroscopy findings: no severe esophageal varices or active peptic ulcer.
- Hemoglobin ≥90 g/L, WBC ≥3.0×10⁹/L, neutrophil ≥1.5×10⁹/L, platelet ≥40×10⁹/L.
- No obvious cachexia; life expectancy \> 3 months.
- Not pregnant; no HIV or syphilis infection.
- Able to understand the study and sign informed consent.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Chifeng Tumor Hospital Coordinator of this site? Confirm its status | Chifeng | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.